Information Letter on Tyverb® (lapatinib): Combination treatment with Tyverb® (lapatinib) less effective in certain settings
2012.12.10
Active substance: lapatinib
Important information on Tyverb® (lapatinib): Comparative data from clinical trials have shown that in certain settings combination treatments containing lapatinib are less effective than those containing trastzumab (Herceptin®).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN